Phase II studies of MVA expressing the tumour antigen 5T4 given with 5-FU based chemotherapies: safety, immunogenicity and clinical responses
Drury N., Shingler W., Chikoti P., Redchenko I., Kelleher M., Hawkins R., Anthoney A., Steven N., Habib N., Griffiths R., Melcher A., Wasan H., Nicholls J., Naylor S., Carroll M., Kingsman S., Harrop R.